Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18505908 | 1.00 | NAAA (0.49) | NAAAPIK3CDCYP1A2ALOX5GGPS1 | |
| SCHEMBL21166299 | 1.00 | NAAA (0.49) | NAAAPIK3CDCYP1A2ALOX5GGPS1 | |
| SCHEMBL24850722 | 0.98 | NAAA (0.48) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL24909681 | 0.98 | NAAA (0.48) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL23594586 | 0.94 | NAAA (0.47) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL25850315 | 0.93 | PIK3CD (0.50) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL21166296 | 0.91 | NAAA (0.43) | NAAAPIK3CDCYP1A2ALOX5 | |
| SCHEMBL24851104 | 0.87 | NAAA (0.49) | NAAAPIK3CDCYP1A2ALOX5GGPS1 | |
| SCHEMBL24926254 | 0.85 | PIK3CD (0.49) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL24850757 | 0.80 | PIK3CD (0.50) | NAAAPIK3CDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20180153872-A1 | HETEROARYL CARBONITRILES FOR THE TREATMENT OF DISEASE | OPKO HEALTH, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153872-A1 | HETEROARYL CARBONITRILES FOR THE TREATMENT OF DISEASE | CLN6, VHL, NPC1 | NAAA 2197/4885PIK3CD 1976/4885CYP1A2 43/4885 |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | NAAA 869/4885PIK3CD 2492/4885CYP1A2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.